A Mylan win in US court could hit Ranbaxy Ranbaxy Laboratories Ltd might lose the 180-day opportunity to exclusively sell its generic version of Novartis AG’s hypertension drug Diovan if a US district court rules in favour of Mylan, which has sued the US Food and Drug Administration (FDA) for refusing it an approval for the generic drug. [News Source]